To ensure that the demographic mix of trial participants matches the epidemiology of the disease being studied, CSL is committed to implementing a Diversity Action Plan (DAP) for all phase III clinical trials for CSL assets. A DAP outlines the strategy for enrolling participants who are members of historically underrepresented populations. This may improve the strength and generalizability of the evidence for all populations affected by the epidemiology of the disease. 

CSL is committed to transparency in this space and has created an easy-to-understand outline of our DAP to share with the public. The DAP provides an overview of the goals for enrollment of participants by age group, sex, and racial and ethnic demographic characteristics based on the prevalence of the disease in the general population, as well as a high-level plan to enroll and retain representative populations.